Abstract Medulloblastoma is a highly aggressive brain tumor and one of the leading causes of morbidity and mortality related to childhood cancer. These tumors display differential ability to metastasize and respond to treatment, which reflects their high degree of heterogeneity at the genetic and molecular levels. Such heterogeneity of medulloblastoma brings an additional challenge to the understanding of its physiopathology and impacts the development of new therapeutic strategies. This translational effort has been the focus of most pre-clinical studies which invariably employ experimental models using human tumor cell lines. Nonetheless, compared to other cancers, relatively few cell lines of human medulloblastoma are available in central repositories, partly due to the rarity of these tumors and to the intrinsic difficulties in establishing continuous cell lines from pediatric brain tumors. Here, we report the establishment of a new human medulloblastoma cell line which, in comparison with the commonly used and well-established cell line Daoy, is characterized by enhanced proliferation and invasion capabilities, stem cell properties, increased chemoresistance, tumorigenicity in an orthotopic metastatic model, replication of original medulloblastoma behavior in vivo, strong chromosome structural instability and deregulation of genes involved in neural development. These features are advantageous for designing biologically relevant experimental models in clinically oriented studies, making this novel cell line, named USP-13-Med, instrumental for the study of medulloblastoma biology and treatment.
Introduction
Primary tumors in the central nervous system (CNS) are frequent in children and adolescents, who have their quality of life significantly affected due to motor, cognitive, and endocrine defects secondary to the Electronic supplementary material The online version of this article (doi:10.1007/s10616-015-9914-5) contains supplementary material, which is available to authorized users. tumors or their treatment (Ward et al. 2014) . Medulloblastoma is the most common malignant brain tumor in young children up to 4 years of age, and one of the leading causes of morbidity and mortality related to childhood cancer (Ostrom et al. 2013) . It is considered by the World Health Organization (WHO) as an aggressive grade IV tumor, characterized by presence of poorly differentiated cell with high proliferative rate and ability to spread throughout the cerebrospinal axis (Louis et al. 2007) .
Approximately 40 % of medulloblastoma patients already have metastasis at diagnosis, which is a predictive factor of poor prognosis (Wu et al. 2012) . Other clinical parameters, such as age at diagnosis and size of residual tumor after surgical resection, are employed to stratify medulloblastoma patients according to the risk of tumor recurrence and to guide their treatment. Despite significant therapeutic improvements in recent decades (Ries et al. 1999) , about 15 and 40 % of patients with either average or high risk of recurrence, respectively, do not respond properly to current treatment, displaying poor overall survival (Zeltzer et al. 1999; Pizer et al. 2011; Othman et al. 2014) .
Improvements in survival rates rely on a better knowledge of the molecular and cellular biology of medulloblastoma, as well as on experimental tools to model this disease and address tumor response to new therapeutic approaches. In the past few years, a significant progress was made in the genetic characterization of medulloblastoma, revealing a high degree of tumor heterogeneity. A new classification proposes to encapsulate such heterogeneity within four medulloblastoma subgroups with distinct molecular/genetic features (Ramaswamy et al. 2011; Kool et al. 2012; Taylor et al. 2012; Northcott et al. 2012; Ramaswamy et al. 2013a; Schroeder and Gururangan 2014; Goschzik et al. 2014; Pietsch et al. 2014) . Concurrently, insights into tumor development, evolution, and resistance to therapy were obtained by the seminal isolation and characterization of highly tumorigenic medulloblastoma cells exhibiting stem cell properties (Singh et al. 2003) .
Pre-clinical studies are valuable to develop new drugs and treatment protocols for medulloblastoma and they invariably employ cell lines, Daoy being the most commonly used human medulloblatoma cell line (Xu et al. 2015) . Compared to other types of cancer, there are relatively few cell lines of medulloblastoma available in central repositories, in part due to intrinsic difficulties in establishing continuous cell lines from pediatric brain tumors, and also because of the significantly lower incidence of these tumors relative to other cancers (Jemal et al. 2010) .
Given that medulloblastoma are highly heterogeneous at the molecular, histological, and clinical levels, novel cell lines are instrumental for studying medulloblastoma biology. Here, we report the establishment and characterization of a new cell line derived from a medulloblastoma patient with advantageous features for pre-clinical studies, namely enhanced aggressive traits, stem cell properties, increased chemoresistance, tumorigenicity in an orthotopic metastatic model, and resemblance of original medulloblastoma behavior.
Materials and methods

Cell line establishment
The USP-13-Med cell line was established from a medulloblastoma specimen of classic histological subtype, derived from a 3 year-old boy admitted for treatment in the Medical School Hospital of the University of São Paulo. The procedure was approved by the Internal Review Board (CEP-IB No. 121/2011), and informed consent was obtained from the patient's parents.
Tumor fragment was mechanically disaggregated with a scalpel, followed by a step of enzymatic disaggregation with collagenase (0.1 %) for 60 min at 37°C to obtain a cell suspension. Patient-derived cells were cultivated with Dulbecco's Modified Eagle Media (DMEM, Gibco, Carlsbad, CA USA) supplemented with 10 % Fetal Bovine Serum (FBS, Gibco), 100 U/ mL Penicillin, 100 lg/mL Streptomycin and 250 ng/ mL Fungizone Ò (Gibco) at 37°C at 5 % CO 2 atmosphere. Cells were subcultivated at 80 % confluence and cryopreserved in liquid nitrogen. An immortalized clonal cell line was obtained after selection of a tumor cell colony developed in the soft agar assay described below. Downstream characterization was performed side-by-side with Daoy (ATCC, Manassas, VA, USA), a well-studied human medulloblastoma cell line.
Anchorage-independent growth of tumor cells Patient-derived cells were subjected to the soft agar colony formation assay in order to estimate anchorage-independent growth of tumor cells, which is a proper in vitro assay for detecting transformed cells. Five hundred cells were seeded over a 0.6 % agarose solution and covered with a 0.3 % agarose solution in a well of a six-well plate. Both solutions contained supplemented media at normal concentrations (10 % FBS, 100 U/mL Penicillin, 100 lg/mL Streptomycin and 250 ng/mL Fungizone Ò ). Plates were incubated at 37°C with 5 % CO 2 in a humidified atmosphere. Media was replaced every 3 days.
Population doubling time
In order to evaluate the proliferative profile of USP-13-Med and Daoy cells, a population doubling level (PDL) assay was performed as recommended by WHO (2010) and described by Schaffer (1990) . The cumulative PDL over 60 cell generations in vitro was calculated by the formula: PDL = Log10 (N/No) 9 3.33 where: N = number of harvested cells after a period of growth and No = number of cells seeded at every new passage. The PDT (population doubling time) was calculated each passage using the following formula recommended by ATCC: DT = t 9 ln2/ln (N/No), where t is the incubation time (ATCC 2014).
Tumorsphere formation assay Cells were seeded onto a 96-well ultra-low attachment plate (Corning, Corning, NY, USA) in DMEM/F12 with B-27 supplement, N-2 supplement, 20 ng/mL EGF and 20 ng/mL bFGF (Gibco), at an initial density of 1.25 9 10 4 cells/mL. Tumorspheres over 50 lm in diameter were counted after 7 days of incubation at 37°C with 5 % CO 2 humidified atmosphere. After 7 days of culture, the tumorspheres were enzymatic dissociated with TrypLE Select (Gibco), fixed for 1 h with 3.7 % paraformaldehyde, and permeabilized with Triton-X100 0.1 % in PBS. CD133/1 antibody conjugated with PE (Miltenyi, Bergisch Gladbach, Germany) and Nestin antibody conjugated with APC (BectonDickinson, Franklin Lakes, NJ, USA) were used to detect CD133
? and Nestin ? cells by flow cytometry. Data were collected with the Guava EasyCyte 5HTTM Flow Cytometer (Millipore-Guava Technologies, Billerica, MA, USA), using GuavaSoft 2.1 and FlowJo v10 softwares. Cells that underwent all the procedures but were not stained with CD133/1 or Nestin conjugated antibody were considered negative controls. The experiment was conducted twice, in triplicate. Plots are representatives of the acquired data.
Determination of cisplatin LC 50 USP-13-Med and Daoy cultures were serum deprived for 24 h for synchronization. A total of 10 4 cells/mL were then seeded in a well of a 6-well microplate and allowed to attach overnight to the surface of the culture plate, prior to a 48 h-treatment with increasing doses of cisplatin (Sigma Aldrich, St. Louis, MO, USA). Apoptotic cells were estimated by the Guava Nexin Ò Annexin V Assay kit (Millipore). Staining was performed according to the manufacturer's instructions, and samples were analyzed in the Guava EasyCyte 5HT
TM Flow Cytometer (Millipore-Guava Technologies), using GuavaSoft 2.1 software. Concentrations lethal to 50 % of cells (LC 50 ) were calculated from dose-response curves.
Cell migration assay
Cell migration was evaluated in vitro using Oris TM Cell Migration Assay Technology (Platypus Techonologies, Madison, WI, USA) according to the manufacturer's procedure. Cells were seeded in high confluence (density of 10 6 cells/mL) and allowed to attach overnight. The Oris TM cell seeding stopper was then removed, exposing the cell migration detection zone. The assay was incubated at 37°C under a 5 % CO 2 humidified atmosphere, for 24 h, to allow cell migration. Photomicrographs were taken at times 0, 12 and 24 h and measurement was performed with ImageJ software, subtracting the migrated area after 12 or 24 h from the original area at 0 h. 3-Dimensional (3D) spheroid cell invasion assay USP-13-Med and Daoy cell invasion capacity were evaluated in vitro using Cultrex Ò 3D Spheroid Cell Invasion Assay (Trevigen, Gaithersburg, MD, USA) following the manufacturer's recommendation. Cells were resuspended in Spheroid Formation ECM at density of 8.10 4 /mL, and added to a 96-well round bottom ultra-low attachment microplate (Corning).
Spheroids were allowed to form for 24 h before invasion matrix and medium with 10 % FBS were added. Photomicrographs were taken on days 0, 2 and 4 after addition of invasion matrix. The amount and extension of the spindle-like protrusions formed by invading cells from the tumor spheroids were considered to calculate the invaded area using ImageJ software, following the manufacturer's instructions.
Chromosomal copy number aberrations DNA from USP-13-Med was extracted using standard cholorophorm/phenol protocol. aCGH was performed using 60 K whole-genome platform (Agilent Technologies, Santa Clara, CA, USA). All procedures were carried out following the manufacturer's recommendation. Microarray scanned images were processed using the Feature Extraction Software (Agilent Technologies). Copy number aberrations (CNAs) were called using the statistical algorithm ADM-2 (sensitivity threshold: 6.7) in Genomic Workbench 6.9 Software. Chromosome deletions and duplications were considered when log2 ratio of Cy3/Cy5 intensities were detected \-0.3 and [0.3, respectively. Hybridization was gender matched.
Global gene expression analysis
Total RNA of USP-13-Med cells was extracted with the RNeasy kit (Qiagen, Venlo, Netherlands), following the manufacturer's protocol. Gene expression profiling of USP-13-Med was evaluated against two samples of non-neoplastic human cerebellum RNA (Agilent Technologies-cat# 540007; Clontech, Mountain View, CA, USA-cat# 636535), used as reference samples. Independent microarray hybridizations were carried out for each sample using Affymetrix GeneChip Ò Human Gene 2.0 ST wholetranscript arrays, measuring both protein coding and long intergenic non-coding RNA transcripts (lincRNA). Hybridization procedures and quality control tests were performed following the manufacturer's protocol. Microarray chips were scanned by GeneChip Ò Scanner 3000 7G System and a quality control was processed by Affymetrix Ò Expression Console Software (Affymetrix, Santa Clara, CA, USA). Differentially expressed genes were identified with the RankProd method, with a p value cutoff of 0.05 adjusted for false discovery rate (Benjamini and Hochberg 1995) , using MeV software v.4.9. Functional Annotation of differentially expressed genes was based on an ontology term enrichment analysis using the DAVID v.6.7, as previously described (Huang et al. 2009 ). Statistical association between being differentially expressed and belonging to a given category was accessed by the Fisher Exact test (p value B0.05). The ontologies used were those defined by the KEGG database of metabolic pathways and by the Gene Ontology Consortium. The probe-to-GO and the probe-to-KEGG mapping were established based on the official annotation provided by the manufacturer.
Orthotopic metastatic model
Both USP-13-Med and Daoy cells were suspended at a density of 10 6 cells/5 lL DMEM and 5 lL of this cell suspension were injected in the right lateral ventricle of BALB/c Nude mice at a ratio of 1 lL/min with a high-precision microsyringe (701RN; Hamilton Company, Reno, NV, USA), by stereotaxic surgery. Control animals were injected with 5 lL of DMEM only. The coordinates used were 1 mm to the right; 0.5 mm posterior of the Bregma and 2.2 mm of depth. The scalp was closed with 2-0 silk suture and the animals were housed under standard controlled conditions (7:00 am to 7:00 pm light/dark cycle; 20-22°C; 45-55 % humidity) with food and water ad libitum. Animals were euthanized after 50 days of inoculation or after the development of neurological deficits. This metastatic model was adapted from Studebaker et al. (2012) . All efforts were made to minimize animal suffering as proposed by the International Ethical Guideline for Biomedical Research (CIOMS/OMS, 1985) . The study was approved by the ethics committee for animal research of the University of São Paulo (CEUA protocol no. 132/2011). Brains were collected, formalin-fixed and paraffin-embedded. A total of 10 randomized 7-lm tissue sections were stained with hematoxylin-eosin for histological analysis. Images were taken in a digital inverted microscope (EVOS Cell Imaging System, Life Technologies, Carlsbad, CA, USA).
Statistical analysis
Statistical analysis of cellular assays was performed with Graph Pad Prism 6 using unpaired Student's t test and statistical significance was established at p \ 0.05. Data are presented as the mean ± SEM.
Results
Proliferative profile of USP-13-Med cells
Establishment of an immortalized human medulloblastoma cell line, named USP-13-Med, was only feasible when screening cells based on their 3D growth properties. Previous attempts to cultivate medulloblastoma cells from fresh specimens were not successful. Cells would stop growing after a few passages under standard monolayer culture conditions. Since cells with enhanced tumorigenic capacity usually survive hostile conditions and display anchorage-independent growth, freshly harvested tumor cells were then transferred from 2D to a 3D culture model in soft-agar, which better mimics the physiological environment of tumor cells.
Under such conditions, few small cell colonies could be observed after 35 days of cell seeding. One well developed tumor cell colony was later picked at day 42 and transferred to one well of a 96-well microplate, for expansion under standard culture condition. The colony-derived cells endured clonal expansion for several generations without signs of replicative senescence (Fig. 1a) . These cells had adherent properties and fibroblastoid morphology somewhat similar of that of Daoy cells (Fig. 1b, c) . This cell morphology was not altered after 30 culture passages. The population doubling time for this cell line was calculated based on a PDL of over 60-70 generations. As observed in Fig. 1a , USP-13-Med cells proliferated faster than Daoy cells, displaying a PDT of 24.5 h, compared to a PDT 29.8 h observed for Daoy cells, under the same experimental conditions.
When subjected to anchorage-independent growth in soft agar, USP-13-Med cells confirmed their highly proliferative behavior, exhibiting a significantly higher efficiency of colony generation compared with Daoy cells (Fig. 1d) . Additionally USP-13-Med colonies were well developed with an average diameter of 150 lm, while Daoy colonies were relatively smaller, inferior of 50 lm in diameter (Fig. 1e, f) .
USP-13-Med cells display stem-like features in vitro
Ability to generate tumorspheres comprised by selfrenewable progenitor-like cells, and increased resistance to chemotherapeutic agents are classic hallmarks of cancer stem cells. USP-13-Med cells demonstrated capacity to generate tumorspheres in vitro with efficiency significantly higher than that of Daoy cells (Fig. 2a) . Under identical culture conditions, tumorspheres from USP-13-Med cells were also larger than Daoy spheres (Fig. 2b, c) . Consistent with what have been reported for medulloblastoma stem cells (Singh et al. 2003) , USP-13-Med tumorspheres were significantly enriched in cells expressing the neuroprogenitor cell marker CD133. Under standard monolayer culture conditions, about 50 % of USP-13-Med cells were already positive for CD133. This proportion increased to nearly 80 % when USP-13-Med cells were transferred to tumorsphere generating media. The same physiological response to environmental stimulus was not observed in cultures of Daoy cells, where the proportion of CD133
? cells remained unaltered despite conditioning in neural stem cell media (Fig. 2d, e) . A subpopulation of cells highly expressing CD133 appeared in tumorspheres of both cell lines. It suggests that the tumorsphere culture condition also stimulates the expression of this marker. A similar result was observed for Nestin expression, which increased in tumorsphere cells (Supplementary Figure 1) .
Furthermore, USP-13-Med cells were also more resistant to cisplatin, a common chemotherapeutic agent used in the clinic, than Daoy cells. Based on the amount of apoptotic cell death after 48 h of cisplatin treatment, the LC 50 calculated for USP-13-Med cells was 126.4 lM, a value about 34 times higher than the LC 50 calculated for Daoy cells (3.7 lM) (Fig. 3) , indicating increased chemoresistance.
Another intrinsic feature of cancer stem-like cells is their high ability to invade tissues. Although USP-13-Med and Daoy cells displayed similar migration properties in a wound healing-like assay (Fig. 4a, b) , when grown as tumor spheroids surrounded by a biological matrix, a condition that better reproduce tumor behavior in vivo, USP-13-Med cells exhibited a significantly higher invasion capacity than Daoy cells (Fig. 4c, d) , revealing a more aggressive phenotype.
USP-13-Med cell behavior in vivo recapitulates main features of metastatic medulloblastoma
Besides being a fast growing tumor, medulloblastoma is also characterized by its infiltrative behavior and ability to spread. When orthotopically injected in the right lateral ventricle of nude mice, mimicking a M1 metastasis stage (cells localized in the cerebrospinal fluid), all animals of both groups developed tumor (Daoy, n = 3; USP-13-Med, n = 4). Three out of four animals injected with USP-13-Med cells developed clinical symptoms (weight loss and gait abnormalities) while, during the experimental period set, animals injected with Daoy cells did not display clinical symptoms. USP-13-Med cells were able to engraft in the brain tissue and generate M2 metastatic tumors characterized by scattered necrotic areas intercalated by high cell density zones. Tumor mass was well developed, well vascularized, and had an irregular shape with several regions of evident intraparenchymal invasion. Although Daoy cells were also able to colonize the brain when injected in the cerebrospinal fluid, the ensuing tumors were more homogeneous, displaying well defined borders. Necrotic zones and vasculature were not evident in the tumor mass and cells had a uniform phenotype (Fig. 5) .
Subchromosomal aberrations in USP-13-Med cells USP-13-Med cells displayed extensive chromosomal copy number aberration. Most chromosomes showed some kind of low level alteration. About 55 losses and Notably, USP-13-Med cells have focused and very high amplifications in chromosome 8, cytoband 8p11.22, harboring ADAM5P and ADAM3A pseudogenes, and in chromosome 3q26.1, in a region containing no genes. Duplications and higher copy number gains in chromosome 2, 6, 7, 11, 12 and 20 were also found. The chromosome 6p21.1 duplication harbors the VEGFA gene functioning in angiogenesis, while the MSI1 gene implicated in medulloblastoma development is located in the duplicated q24.11-q24.32 region of chromosome 12. Of note, the duplicated segments of chromosome 12 also harbor several non-coding RNAs of unknown function.
Marked apparently homozygous deletions in chromosomes 1 (1p32.3), 4 (q13.2, q22.2, q34.3, q35.2), 9 No significant copy number aberrations were detected in cytoband locations relative to TP53 (17p13.1), nor in APC (5q22.2), MYC (8q24.21), MYCN (2p24.3), CTNNB1 (3p22.1), GLI2 (2q14.2), and CDK6 (7q21.2), which have been found in specific molecular subtypes of medulloblastoma. A deletion, possibly in mosaic, was detected in 13q14.2, encompassing RB1, and low copy gains were detected in 9q22.32, 12q12-q21.1, and 14q22.1-q32.33, harboring, PTCH1, GLI1, WNT1, and OTX2, respectively.
Global gene expression profiling of USP-13-Med cells
A total of 984 genes were found differentially expressed in USP-13-Med cells compared with normal cerebellum, with a fold change value of at least 2. As listed in Supplementary Table 2, there were 448 upregulated genes and 536 downregulated genes. The list of upregulated genes was significantly enriched in genes functioning in cell cycle regulation, cytoskeleton, extracellular matrix, protein metabolism, and p53 signaling, whereas the list of downregulated genes was enriched in genes involved in cell adhesion, neuronal signaling, MAPK and calcium signaling pathways (Fig. 7a) . Although, in both gene lists, no significant enrichment in genes related to the WNT or SHH signaling was detected, roughly 20 % of the downregulated genes encode proteins involved in neural system development, encompassing genes with specific functions in neurogenesis, neural differentiation, neuron migration, synaptogenesis, and other closely related functional categories, all of which being significantly overrepresented in the list of differentially expressed genes (Fig. 7b) .
Additionally, classic oncogenes such as NRAS, RRAS, MET, and AURKB, as well as genes encoding proteins related with cancer stem cell properties, including the kinase MELK, the multidrug resistance Fig. 6 Major chromosomal copy number aberration found in USP-13-Med cells. Ideograms of chromosomes displaying major alterations in copy number are shown. Homozygous deletions were found on chromosomes 1, 4, 9 and 12, while an amplification was observed in chromosome 8. Blue or red dots in the aCGH profiles of these chromosomes represent gains or losses, respectively. (Color figure online) transporter ABCC4, the radioresistance protein EZH2, the DNA repair enzyme RAD50, and the antiapoptotic protein BIRC5, were found overexpressed in USP-13-Med cells.
Discussion
Tumor cell lines are very important tools to address fundamental questions in cancer biology and develop new therapies. In the case of pediatric brain tumors such as medulloblastoma, only a few cell lines have been more extensively used in research (Xu et al. 2012 (Xu et al. , 2015 . Medulloblastoma, however, comprise a group of highly heterogeneous tumors, as revealed by recent gene expression profiling and exome sequencing studies (Kool et al. 2012; Baron 2012; Mardis 2012; Williams et al. 2013) . Current molecular subtypes of medulloblastoma are differentially associated with treatment response, frequency of metastasis, and survival rate (Kool et al. 2012; Northcott et al. 2012; Ramaswamy et al. 2013b ). Thus, a diversity of cell lines displaying different characteristics and molecular/genetic anomalies is required to properly cover the heterogeneity of medulloblastoma.
The USP-13-Med cell line, obtained from a 3 year old boy with classic medulloblastoma, display typical cancer hallmarks that contribute to tumor maintenance and aggressiveness Weinberg 2000, 2011) . In particular, this cell line demonstrated an aggressive tumor behavior in vitro, revealed by a significantly higher cell proliferation rate compared to Daoy cells. The population doubling time of USP-13-Med (24.5 h) is also shorter than those reported for other commonly used medulloblastoma cell lines, such D283-Med (52.5 h) (Friedman et al. 1985) , CHLA-259 (76 h) (Xu et al. 2012) , and MHH-MED-2 (119 h) (Pietsch et al. 1994) . Under selective culture conditions, USP-13-Med cells still demonstrated significantly higher capacity to form colonies in soft agar, as well as tumorspheres in neural stem cell medium, compared to Daoy cells. Notably, contrary to Daoy, USP-13-Med line was able to respond to environmental stimuli, enriching the proportion of cells expressing the neural stem cell marker CD133 under tumorsphere-generating conditions. Some of the chromosomal abnormalities found in USP-13-Med cells are in concert with these observations. While gain in 14q22.1-q32.33, harboring the OTX2 oncogene and deletion of the tumor suppressors CDKN2A and CDKN2B in chromosome 9p21.3, CDKN2C in chromosome 1p32.3, and of the cell cycle repressor E2F7 (Di Stefano et al. 2003) in chromosome 12q21.2 would favor increased cell proliferation rates, additional copies of the MSI1 gene due to gains in the 12q24.11-q24.32 would favor a more primitive, neural stem-like cell phenotype. Besides being a neural stem cell marker (Glazer et al. 2012) , the MSI1 protein also promotes cell proliferation by suppressing p21, p27 and p53 translation (Liu et al. 2014) . Upregulation of MELK, encoding a serine/threonine kinase with critical role in cancer stem cell proliferation and survival (Ganguly et al. 2014) , was also detected in USP-13-Med cells. In brain tumor cells, both MSI1 ) and MELK (Marie et al. 2008 ) upregulation, as well as capacity to generate tumorspheres in vitro (Panosyan et al. 2010) , have been correlated with poor prognosis. Self-renewable CD133
? medulloblastoma stem cells are also known to be more efficient in initiating tumors in vivo (Singh et al. 2004) . Furthermore, cancer stem cells tend to form tumors that better resemble the original anatomopathological features of the human disease, displaying aggressive features such as extensive necrotic areas, invasion to adjacent tissue, evident angiogenesis, and cellular heterogeneity (Galli et al. 2004) . Consistently, when orthotopically inoculated in the lateral brain ventricle, USP-13-Med cells were able to generate large tumors characterized by presence of necrotic areas, evident vasculature, and irregular board plenty of cells invading the brain parechyma. This high degree of intraparenchymal invasion is supported by the significantly enhanced 3D invasion capacity observed for USP-13-Med spheroids, compared to Daoy. This is an important USP-13-Med trait, since cell motility is also implicated in tumor aggressiveness and ability to metastasize (van Zijl et al. 2011; Polyak and Weinberg 2009; Dave et al. 2012) . Several small tumor islands could be observed in some brains of animals injected with USP-13-Med cells. These structures could represent either new metastatic lesions or protrusions of the main tumor. In any case, these are features indicative of more invasive and aggressive tumors.
Currently, treatment of medulloblastoma is multimodal, consisting in tumor resection followed by chemotherapy, with cisplatin being one of the main chemotherapeutic agents used (Ramaswamy et al. 2015) . Radiotherapy may also be applied depending on the age of the patient, with doses varying according to clinical staging (Gerber et al. 2014; Ramaswamy et al. 2015) . The 5-year disease-free survival range from about 85 % in average risk patients to 60-65 % in high risk patients (Crawford et al. 2007; Remke et al. 2013) . Nonetheless, up to 40 % of patients do not respond to treatment and present tumor recurrence, which often leads to a poor survival outcome (Taylor et al. 2003; Lannering et al. 2012; Tarbell et al. 2013; Othman et al. 2014) . The enhanced resistance of USP-13-Med cells to cisplatin is, therefore, another interesting trait of this cell line that could be explored to study chemoresistance and to screen new drug candidates.
This increased resistance to apoptosis induced by chemotherapy may be explained, at least in part, by some of the chromosomal abnormalities found in USP-13-Med cells. The loss of chromosome 12q21.2 encompasses NAV3, whose silencing was recently reported to inhibit apoptosis of breast cancer cells (Cohen-Dvashi et al. 2015) . USP-13-Med cells also seem to have dysfunctional p53 signaling. Despite the native p53 status of these cells, multiple deletions affecting genes encoding upstream and downstream mediators of p53 signaling were identified. For instance, the deletion of CDKN2A, which encodes the tumor suppressors p14 and p16 by alternative splicing, may affect the p14-mediated accumulation of p53 and ensuing activation (Midgley et al. 2000) . Noteworthy, deletion of 9p21.3 harbors the mirR-491, which was recently reported to have pro-apoptotic activity by targeting both BCL-XL and MCL1 proteins in chemoresistant ovarian cancer cell lines (Denoyelle et al. 2014) , as well as miR-31, whose genomic deletion has been correlated with defects in the p53 pathway in cancer cells (Creighton et al. 2010) . Decreased miR-31 expression was also reported to enhance chemoresistance of ovarian cancer cells due to up-regulation of its target, receptor tyrosine kinase MET (Mitamura et al. 2013) . Finally, gains in 12q12-q21.1 encompassing MDM2 would favor p53 degradation (Pant and Lozano 2014) , while gains in 12q24.11-q24.32, as mentioned above, would favor inhibition of p53 translation by MSI1 (Liu et al. 2014) .
Interestingly, USP-13-Med cells have few genetic aberrations affecting proteins of both WNT (WNT1) and SHH (PTCH1 and GLI1) signaling pathways. Nonetheless, low copy gain of OTX2 was also detected in USP-13-Med cells. Previous studies reported that OTX2 copy number gain was not associated with WNT or SHH medulloblastoma subtypes (Adamson et al. 2009 ), but rather with either group 3 or 4 tumors . The metastatic behavior USP-13-Med cells is also more coherent with groups 3 and 4, since tumors of the WNT and SHH subgroups are rarely metastatic . Since neither amplification of MYC, typical in group 3 tumors, nor of MYCN were found in USP-13-Med cells, the CNA profile of these cells are more consistent with that of group 4 tumors. In agreement with the CNA status, the global gene expression profiling of USP-13-Med cells revealed enrichment in differentially expressed genes involved in neural development and other neurogenesis-related functions which, again, have been correlated with group 4 medulloblastomas . Notably, genes involved in WNT or SHH pathways were not significantly overrepresented in the list of differentially expressed genes.
Compared with other subgroups, medulloblastomas categorized in group 4 are more heterogeneous and the molecular pathogenesis of such tumors is uncertain. Confirmation of this molecular classification would add another important value to USP-13-Med cell line as a biologically relevant model since, from the 15 available medulloblastoma cell lines with known molecular classification, only one (CHLA-01-MED) belongs to group 4 (Xu et al. 2015) .
In summary, we established a new human medulloblastoma cell line characterized by a high proliferative activity, high colony formation efficiency, enhanced ability to generate tumorspheres enriched in CD133
? cells, as well as increased invasion capacity and chemoresistance, when compared to the well-established cell line Daoy. USP-13-Med was also tumorigenic in vivo in an orthotopic metastatic model, generating well developed tumors with extensive necrosis, evident vascularization and intraparenchymal invasion, typical of aggressive tumors. Numerous chromosomal gains and losses were detected, affecting oncogenes, tumor suppressors, neurogenesis genes, microRNAs, as well as long non-coding RNAs of unknown function. Overexpression of classic oncogenes and cancer stem cell-related genes were also found. Cell behavior, chromosomal aberrations, and global gene expression profile more closely related to those of group 4 medulloblastomas were identified in this cell line. All these features are highly advantageous for pre-clinical studies aiming at improving our understanding of medulloblastoma development and testing new therapeutic strategies. The use of this novel cell line by the scientific community in future studies shall also refine its molecular classification.
